Can a triple therapy outsmart Hard-to-Treat esophageal cancer?

This trial is investigating whether adding an experimental immunotherapy drug, retlirafusp alfa, to standard chemotherapy and radiation can help people with locally advanced esophageal squamous cell cancer that cannot be surgically removed. Participants will receive two cycles of the drug with chemotherapy before the standard chemoradiation, followed by maintenance immunotherapy for up to a year. The main goal is to see if this approach improves the chance of living without the cancer progressing for at least one year.